Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: May 27, 2017

DrugPatentWatch Database Preview

Rivastigmine - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for rivastigmine and what is the scope of rivastigmine freedom to operate?

is the generic ingredient in three branded drugs marketed by Alvogen Malta, Novartis, Watson Labs, Dr Reddys Labs Inc, Sun Pharm Inds Ltd, Cadila Pharms Ltd, Macleods Pharms Ltd, Apotex Inc, Aurobindo Pharma Ltd, Orchid Hlthcare, and Alembic Pharms Ltd, and is included in thirteen NDAs. There are three patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Rivastigmine has thirty-two patent family members in twenty-six countries.

There are thirty-two drug master file entries for rivastigmine. Five suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for Generic Name: rivastigmine

Drug Master File Entries: see list32
Suppliers / Packagers: see list5
Bulk Api Vendors: see list45
Clinical Trials: see list26
Patent Applications: see list6,213
Therapeutic Class:Antidementia Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:rivastigmine at DailyMed

Pharmacology for Ingredient: rivastigmine

Tentative approvals for RIVASTIGMINE

Applicant Application No. Strength Dosage Form
► Subscribe► Subscribe2MG/MLSOLUTION; ORAL
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharm Inds Ltd
rivastigmine tartrate
CAPSULE;ORAL077131-001Oct 22, 2007ABRXNoNo► Subscribe► Subscribe
Macleods Pharms Ltd
rivastigmine tartrate
CAPSULE;ORAL203148-003Aug 22, 2014ABRXNoNo► Subscribe► Subscribe
Sun Pharm Inds Ltd
rivastigmine tartrate
CAPSULE;ORAL077131-002Oct 22, 2007ABRXNoNo► Subscribe► Subscribe
Cadila Pharms Ltd
rivastigmine tartrate
CAPSULE;ORAL203844-004Feb 13, 2017ABRXNoNo► Subscribe► Subscribe
Dr Reddys Labs Inc
rivastigmine tartrate
CAPSULE;ORAL077130-002Oct 31, 2007ABRXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Anticipate P&T budget requirements
  • Formulary management
  • Set up watchlists for daily email updates

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:

Google Plus